Skip to main content
. Author manuscript; available in PMC: 2008 Oct 1.
Published in final edited form as: Cancer Cell. 2007 Oct;12(4):367–380. doi: 10.1016/j.ccr.2007.08.031

Table 1.

Mutations identified in CMML patients

Mutation No. of patients1 Percentage (%)
FLT3-ITD2 6 3.1
FLT3-AL3 0 0
N-RAS, K-RAS 38 19.6
1

total number of patients analyzed (n=194)

2

ITD, internal tandem duplication

3

AL, activation loop

*

FLT3-ITD and N-RAS/K-RAS mutations identified were mutually exclusive